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Abstract
Drug-resistant tuberculosis (TB) remains a major challenge to global health and to healthcare in the UK. In 2014,
a total of 6,520 cases of TB were recorded in England, of which 1.4 % were multidrug-resistant TB (MDR-TB).
Extensively drug-resistant TB (XDR-TB) occurs at a much lower rate, but the impact on the patient and hospital is
severe. Current diagnostic methods such as drug susceptibility testing and targeted molecular tests are slow to
return or examine only a limited number of target regions, respectively. Faster, more comprehensive diagnostics
will enable earlier use of the most appropriate drug regimen, thus improving patient outcomes and reducing
overall healthcare costs. Whole genome sequencing (WGS) has been shown to provide a rapid and comprehensive
view of the genotype of the organism, and thus enable reliable prediction of the drug susceptibility phenotype within
a clinically relevant timeframe. In addition, it provides the highest resolution when investigating transmission events in
possible outbreak scenarios. However, robust software and database tools need to be developed for the full potential
to be realized in this specialized area of medicine.
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Background
Early observations made in 2008 [1] predicted the poten-
tial for whole genome sequencing (WGS) to transform
tuberculosis (TB) diagnostics, when the then recent use
of “next generation” sequencing technology to analyse
extensively drug-resistant (XDR) isolates of Mycobacter-
ium tuberculosis was summarized. Such has been the
speed of technological advances that the description of 1
gigabase (Gb) of sequence as “staggering” in 2008 is now
dwarfed by the current state-of-the-art machines, produ-
cing up to 15 Gb on the benchtop MiSeq and 1,500 Gb
on HiSeq 4000. The inevitable economies of scale have
therefore led to a rapid drop in costs, thus opening up
microbiology diagnostics to direct sequencing applications.
In order to consider the potential for WGS to improve
diagnosis, treatment and management of TB in a clinical
setting, it is useful to understand the current diagnostic
workflow. The exact details of this process (and thus the
potential impact of WGS) vary between different settings
and countries, so we discuss this in the context of
St George’s Hospital, London, UK. In 2014, a total of 6,520
cases of TB (incidence of approximately 12 per 100,000)
were recorded in England, of which 1.4 % were multidrug-
resistant TB (MDR-TB); defined as resistant to isoniazid
(INH) and rifampicin (RIF) [2]. However, both TB (30 per
100,000) and MDR-TB levels are higher in London. Exten-
sively drug-resistant TB (XDR-TB) occurs at a much lower
rate, but the requirements for effective clinical management
and treatment of the MDR-TB and XDR-TB and the public
health management of such cases are even more onerous.
Current practice
The standard procedure for a case of TB at St George’s
Hospital would be as follows. A patient is referred from
a primary care setting, a chest clinic or a local hospital
as having suspected pulmonary TB, or attends of their
own volition. A sputum sample is taken, examined by
microscopy for acid-fast bacilli (AFB) and a BacT/Alert
(Organon Teknika Corporation, Durham, NC, USA) [3]
liquid culture inoculated. If TB is clinically suspected
then treatment will be started immediately; otherwise,
the smear results will be returned within 1–2 days, and if
positive, the patient is started on standard TB treatment
according to WHO guidelines [4, 5].
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If the M. tuberculosis is fully sensitive, this is the cor-
rect treatment regimen. However, there is a significant
chance that antibiotic resistance may be present, and if
true, the standard treatment may be completely ineffect-
ive, or if only partially so, could make the development
of resistance more likely. Therefore, when BacT/Alert
cultures become positive, usually within 1–2 weeks, they
are sent to the UK’s national reference laboratory (NRL)
for first-line drug phenotypic susceptibility testing
(DST). Results are returned within 2–3 weeks, but if evi-
dence of resistance is found then second-line DST is
begun, returning after a further 2–3 weeks. It can there-
fore take up to 8 weeks after presentation before a full
DST profile is available for resistant cases.
In order to speed up this process, St George’s Hospital
carries out molecular tests to identify likely MDR-TB
cases. Following microscopy, an AFB smear-positive spu-
tum is also tested for genetic markers of RIF resistance
using the Xpert® MTB/RIF assay (Cepheid, Sunnyvale,
CA, USA) [6]; results are available within two days. Other
hospitals may wait for a positive culture before performing
an Xpert® MTB/RIF assay, with the subsequent delays that
may then occur. A negative Xpert® MTB/RIF assay result
for RIF resistance leads to continuation of standard drug-
sensitive treatment, with subsequent public health action
to trace contacts, assess exposure with Mantoux skin tests
and offer INH prophylaxis, where appropriate. A positive
Xpert® MTB/RIF assay result indicating RIF resistance
suggests that this is now a likely case of MDR-TB, an as-
sumption that has considerable clinical and public health
consequences. It leads to an assessment of the risk factors
for resistance and the clinical condition of the patient, in
order to decide whether to cease first-line drug treatment
and switch to a second-line drug regimen [4, 5] at this
stage or wait for further molecular confirmation of resist-
ance. Furthermore, heightened infection control measures
are implemented and extended public health question-
naires initiated.
Other molecular tests are available, notably the Geno-
Type MTBDRplus (Hain Lifescience, GmbH, Nehren,
Germany) [7] which identifies selected markers for INH
resistance in addition to RIF, further confirming MDR-
TB, and the GenoTypeMTBDRsl (Hain Lifescience) [8]
which also identifies selected resistance markers for
fluoroquinolones, aminoglycosides and ethambutol, indi-
cative of XDR-TB. In our context, these tests are available
from the NRL but have to be specifically requested.
WGS has two main overlapping uses in clinical
microbiology and public health: i) identification of ge-
notypes which can be used to predict drug-resistant
phenotype; and ii) the determination of genetic relatedness
which can identify transmission chains in potential out-
break scenarios. Both of these can have direct patient
benefits.
Genotype–phenotype prediction
The prediction of antibiotic resistance phenotype from
genotype is not yet a solved problem; however, it is a
more straightforward task for M. tuberculosis than for
other species due to a lack of horizontal gene transfer.
Indeed, drug resistance is generally thought to be medi-
ated only through mutations in specific gene targets.
The key, therefore, is to identify those single nucleotide
polymorphisms (SNPs) which are responsible for, or
strongly associated with, resistance.
Many studies have been performed identifying individual
markers of resistance; however, more recently, several large
sequencing studies have analysed clinical isolates and
correlated SNPs to phenotypic drug sensitivity results,
calculating predictive sensitivities and specificities of
sets of SNPs [9–11]. In this context, specificity describes
the likelihood that SNPs identified lead to resistance, while
sensitivity describes the proportion of resistant cases that
are identified through that set of SNPs. But the confidence
for which a prediction can be made has been shown to
vary according to not only drug class but also different
members of these classes. This is slightly complicated
by the fact that the gold standard (culture) has its own
error rate [12].
The aforementioned molecular diagnostic tests are
targeted methods for predicting the phenotype of the
organism from the detected genotype. These examine a
limited number of sites known to be associated with
varying levels of resistance to the specific drugs mentioned.
False negatives can arise, for example, when any rifampicin-
resistant (RIFR) mutations that lie outside the rpoB RIF
resistance-determining region (RRDR), such as the I491F
mutation in RpoB [13, 14], are not detected by the Xpert®
MTB/RIF assay leading to the isolate being incorrectly
called susceptible. Similarly, false positives can arise when a
polymorphism in the RRDR region of rpoB is detected and
RIFR predicted when they are either completely rifampicin-
sensitive (RIFS) or have a low level of resistance that could
be overcome by an appropriately increased dosage (see
below). Furthermore, it is important to understand that
resistance is not a binary phenomenon, and the variable
impact of individual mutations on the minimum inhibitory
concentration (MIC) raises the possibility of designing
personalized treatment regimes, for example:
i) It has been established that INH resistance,
predominantly mediated through loss of catalase-
peroxidase activity via mutations in katG, produce
high-level resistant strains (MIC: 2–8 μg/ml INH)
and that the KatG S315T substitution occurs in
50–95 % of INH-resistant isolates [15]. However,
mutations in the inhA gene or promotor region
produce low-level resistant strains (MIC: 0.2–
0.5 μg/ml) occurring in 8–43 % of INH-resistant
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isolates. Therefore, if a katG high-level resistance
mutation is detected, isoniazid therapy should not be
included and could be substituted with prothionamide.
Prothionamide has the same drug target as INH,
namely InhA, but it is activated from the pro-drug
form to the active drug by a different enzyme, EthA,
and mutations in the ethA gene might contraindicate
the use of prothionamide. If, however, an inhA
promotor mutation is present suggesting low-level
resistance, then INH could remain in the regimen
but at a higher dosage as INH has a high therapeutic
margin.
ii) Moxifloxacin is a second-line drug included in
standard MDR-TB regimens, and specific mutations
in the gyrA gene confer resistance often suggesting
the presence of an XDR-TB isolate. However, different
mutations in gyrA impact MIC values differently
according to the quinolone type [16]. For example,
an MIC value for moxifloxacin of 1 μg/mL has been
shown in isolates with the A90V substitution in
GyrA. This would be called resistant by conventional
phenotyping using the standard breakpoint of
>0.5 μg/ml, but Feasey et al. [17] showed successful
treatment by increasing the dose of moxifloxacin
from 400 to 600 mg in order to achieve in vivo drug
levels above the MIC. Subsequent identification of this
A90V mutation in other clinical isolates could be
used as evidence to indicate similar dosage alterations
for effective treatment in the face of a resistant
DST result.
iii)Mutations in the 89 base pair RRDR of rpoB confer
a range of resistance phenotypes with large variations
in MICs [18, 19]. Knowing the exact mutation and
subsequent amino acid change is therefore crucial. A
case of possible MDR-TB could be indicated by a
positive Xpert® MTB/RIF assay and called RIFR because
of a SNP in the RRDR that is different from wild-type,
identified by one of the five probes used in that
test. This SNP could be a simple phylogenetic
polymorphism independent of resistance, or a SNP
associated with low-level RIFR. Such a false positive
result would wrongly indicate MDR-TB and exclusion
of RIF in the initial regimen prior to phenotypic
susceptibility testing. For example, MIC data for a
range of non-synonymous SNPs at codon 526 has
been reported ranging from 1–256 μg/ml [18, 19].
Thus, RpoB H526N, an allele we recently found in
a M. tuberculosis patient isolate, has an MIC of
0.25 μg/ml, so rifampicin can still be included in
the regimen despite the Xpert® MTB/RIF assay
returning a resistant result at initial diagnosis.
Furthermore, different alleles have different levels
of cross-resistance to rifabutin (RFB), a semi-synthetic
derivative of RIF [19, 20]. For example, mutation
H526L is associated with a RIFR/RFBS pattern and
might inform the substitution of RFB into a therapy
regimen. Sequence data might thus direct the use
of either RIF or RFB depending on the exact allele
identified.
A recent and comprehensive report from the TBNET
and RESIST-TB networks collated genotype–phenotype
data from literature and electronic databases and reached
a consensus about reporting standards in the clinical use
of molecular DST results [21]. The report summarised the
clinical implications of mutations detected by molecular
methods and provided much needed clarity on the issue
of how genotypic data can be interpreted in terms of TB
drug regimes.
Determination of genetic relatedness
In the UK, outbreak identification is currently determined
using the mycobacterial interspersed repetitive unit-variable
number tandem repeat (MIRU-VNTR) method [22], which
can suggest clusters of isolates but lacks the resolution to
be certain of possible transmission events. The identifica-
tion of such events clearly has a role in public health inter-
vention, but can also directly benefit the patient if clinical
outcome data is available for the strain in question, ensur-
ing that patients and infected contacts can be isolated and
initiated on the most effective treatment as quickly as pos-
sible. We have experienced this scenario at St George’s
Hospital; WGS identified an XDR-TB strain from a hospital
in-patient with smear-positive pulmonary TB and no risk
factors of MDR/XDR-TB, as identical to a known XDR-TB
strain that we had previously sequenced. The patient was
switched to an XDR-TB regimen and subsequent sputum
samples showed culture conversion.
Several studies have attempted to validate WGS for
public health interventions. Gardy et al. [23] demonstrated
the limited resolution of MIRU-VNTR for outbreak inves-
tigation by sequencing 32M. tuberculosis isolates from a
threeyear outbreak of TB in British Columbia, Canada.
WGS data clearly showed the presence of two distinct lin-
eages of M. tuberculosis with identical MIRU-VNTR types,
although they had both likely descended from a historical
common ancestor. Furthermore, the integration of WGS
with social network information identified several trans-
mission events and the presence of super-spreaders, lead-
ing to the conclusion that the outbreak coincided with a
recorded increase in crack cocaine usage.
Török et al. [24] investigated two cases of MDR-TB as-
sociated with a language school in Cambridge, UK. The
cases had an epidemiological link through the school,
but there was a discrepancy in phenotypic results; one
was determined streptomycin-resistant and the other
sensitive. The UK’s National Mycobacterial Reference
Laboratory showed that both isolates were of the Beijing
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lineage and of the same MIRU-VNTR type; however, the
phenotypic difference suggested that they were different
strains. Subsequent WGS showed that the isolates did
not display any differences in SNPs, suggesting a missed
direct or indirect transmission event. This case high-
lights a particular problem with the reliability of pheno-
typic testing, and the authors suggest that MICs close to
the breakpoint for streptomycin could have affected the
reproducibility and thus the discrepancy between the
two isolates.
Walker et al. [25] undertook a larger, retrospective
observational study using WGS to delineate TB clusters
within 390 isolates from 254 patients archived over a
17-year period from the central UK region. By analysing
the patterns of mutations the study enabled an inference
about direction of transmission within outbreaks and also
identified the existence of potential super-spreaders in
several of the clusters investigated.
Pankhurst et al. [26] identified several outbreak sce-
narios which had been previously missed by standard
routine methods, and demonstrated that WGS in rou-
tine use can identify transmission networks and direct
better public health interventions.
Clinical consequences
Clinical management of antibiotic-resistant TB is complex.
The drugs are often poorly tolerated, and side-effects
include ototoxicity, nephrotoxicity, hepatitis, diarrhoea,
vomiting and psychological disturbances [27]. Add-
itionally, the requirement for an injectable drug in the
regime requires the insertion of a central long line,
which exposes the patient to an increased risk of infec-
tion and venous thrombosis. According to UK national
guidelines [28], patients should be isolated in negative
pressure, HEPA-filtered single occupancy rooms until 3
weekly negative smears have been obtained that are
ideally also culture negative. At St George’s Hospital we
wait for the repeated respiratory samples to be culture-
negative after a 6 week incubation. These measures are
unpleasant for the patient, expensive for the hospital
and compliance can be difficult. Where drug resistance
is suggested, second-line MDR treatment is started in a
complete absence of detailed resistance information,
and DST results only appear up to 5–8 weeks after
presentation. In our experience, the initial regimen is
often not optimal, and when XDR-TB cases are encoun-
tered may be completely ineffective. Even when optimal, it
may be desirable to change because of drug side-effects,
and to do this in the absence of resistance information
is not ideal.
The routine use of a genotypic RIF testing gives a fas-
ter indication of the suitability of the drug regimen. In
settings where this is not done, DST for MDR-TB cases
will be carried out in two phases, leading to further
delays. In these cases, patients are likely to have spent
the first 3–5 weeks on ineffective first-line drugs, and
will only have generic MDR treatment for the subse-
quent 2–3 weeks.
False negative and false positive tests for resistance
have significant implications for the patient. Incorrectly
assigning a patient to drug-sensitive TB means many
weeks of infective treatment and subsequent further resist-
ance developing, whilst incorrectly assigning to a regime
for drug-resistant TB has implications due to the drug
toxicities and stringent public health measures imple-
mented. The consequences of such errors are severe,
especially when it is considered that these will only be
corrected once the full DST profile is received, up to
8 weeks later. WGS avoids these specific problems by
presenting an unbiased view of the whole genome; all
sites are examined simultaneously, in a timeframe consid-
erably shorter than current methods. WGS interpretation
does, however, require expertise in bioinformatics and
data analysis tools that may not be available in all settings.
Several studies have investigated the potential impact
of WGS on patient benefit by attempting to predict drug
susceptibilities from the isolate genotypes [26, 29–31].
Witney et al. [29] demonstrated that WGS can be used
to provide treating physicians with valuable information
in a clinically relevant timeframe, several weeks before
DST results can be returned. More recently, Pankhurst
et al. [26] demonstrated routine use of WGS and calcu-
lated that the system cost £481 (WGS alone), £518 (DST
alone) or £540 (DST and WGS), demonstrating that
WGS can be economically viable. Furthermore, these
differences in cost are tiny when compared to the costs
of in-patient treatment for drug-resistant TB; at St
George’s Hospital, we estimate that treating a TB patient
in the airflow-controlled ward costs £900 per day, not
including the cost of the often expensive drugs required
for MDR and XDR cases. The case for any intervention
that has the potential to save weeks of patient care is
therefore clear.
All the studies described so far have applied WGS to
cultured isolates; however, a further 1–2 weeks could be
saved if the culture step is eliminated. WGS applied direct
to sputum is a difficult problem due to the low number of
organisms and the presence of contaminating human and
non-mycobacterial DNA. To address this problem, Brown
et al. [32] used DNA sequence capture with biotinylated
RNA bait oligonucleotides, spanning the entire M. tuber-
culosis genome, followed by amplification and sequencing
of the captured DNA. This method was applied to 24 TB
sputum specimens and showed good on-target reads and
depth of coverage for 23 samples with associated accurate
prediction of drug resistance mutations. Evidence for a
mixed infection with two strains in one sample was also
predicted from the genome sequence data and this
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indicates another potential read-out of WGS that is unlikely
to be obtained through other methods. Such direct use
of WGS has been proposed as the basis for personalizing
therapy for drug-resistant TB [33].
WGS is not a stationary technology [34]; development
of miniaturized sequencing platforms such as the MinION
from Oxford Nanopore Technologies (Oxford, UK) will
eventually democratize the implementation of WGS in the
clinical management of TB by substantially reducing the
cost, making the economic, technical and clinical argu-
ments for WGS implementation incontrovertible [35].
Bioinformatics
Bioinformatic analysis is a key part of the WGS process,
and for optimal clinical use, issues within the analysis
pipelines and database resources need to be addressed.
The analysis process can be broken down into three
steps: i) alignment of the DNA sequence data to a reference
genome, normally the H37Rv strain of M. tuberculosis; ii)
variant site calling which determines the probability that a
SNP is correctly identified in the sequence and is not due
to a random error introduced during the sequencing
reaction; and iii) resistance prediction or phylogenetic
reconstruction. Numerous alignment tools are available
and all have strengths and weaknesses [36], such that
the choice is invariably made by personal preference.
Variant site calling commonly involves either SAMtools
[37], FreeBayes [38] or GATK [39], and resistance predic-
tion is often implemented using custom software, com-
paring identified mutations with databases of known
resistance-conferring SNPs. Phylogenetic reconstruction
from sequence data is not a new problem, but when ap-
plied to clinical WGS data some work still needs to be
done with regards to estimating the error when determin-
ing SNP number differences between isolates in potential
transmission chains; the identification of a transmission
event can have significant downstream clinical and public
health impact.
Many software pipelines have been developed and are
in use in individual laboratories or available via web in-
terfaces [9, 39]. However, the future implementation of
WGS in clinical practice will depend on the develop-
ment of robust and validated software tools that are easy
to use and interpret in the diagnostic context. Promising
examples are under development that can predict a
phenotype within minutes of uploading sequence data,
for example Mykrobe [40]. Efforts are also under way to
assess and standardize methods, for example the Global
Microbial Identifier group [41] initiated an open profi-
ciency test in 2015, providing standard DNA material or
sequence data for processing by participants. Although
this does not currently include M. tuberculosis, the align-
ment and site calling steps described above are generally
organism-independent. However, such standard reference
data are essential to develop consensus, thus encouraging
better inter- and intra-laboratory reproducibility.
The reliability of the genotype–phenotype prediction
is dependent not only on good correlation data but also
on good database resources to allow easy access to such
data [42]. TBDReaMDB [43] was the first TB-specific
database of drug resistance-conferring mutations, cre-
ated in 2009, and more recently updated in 2014. It was
collated through literature searches; however, it now ac-
cepts submissions from external users. TBDReaMDB
does not attempt to validate target mutations, instead
only cataloguing studies examining mutations and genes
of interest. For genotyping by WGS to become effective,
validated and continuously updated databases need to be
developed and made available; successful examples in-
clude the public HIV Drug Resistance Database [44].
The recently funded ReSeqTB project [45], which aims
to implement a single repository for validated TB drug-
resistant correlations, may fulfil this role; however, it is
still in the early stages of development. Furthermore, it
is interesting to note that the aforementioned HIV data-
base also includes data on genotype-clinical outcome
correlations. Maybe this would be a useful addition to
any TB mutation repository, since sharing successful
treatment options for already sequenced strains could be
as effective as predicting phenotype solely from geno-
type. The mechanics of the interaction between the soft-
ware tools and global databases of resistance mutations
and phylogenetic information is yet to be determined.
However, the true power of WGS will not be realised
unless open and integrated systems are put in place.
Arguably WGS could be used to expand the current
rapid, targeted molecular methods by improving the pre-
dictive power of any identified mutation, but whereas the
targeted molecular approach requires constant technical
development to maintain a comprehensive mutation
detection list, WGS requires only updates to its predictive
algorithm, thus improving the diagnostic power more
rapidly.
Conclusions
The advantages of WGS in the TB diagnostic workflow
are clear when compared to standard DST; results can
be returned several weeks earlier and, in the future, this
will only become faster and cheaper. Compared to current
molecular tests, until WGS can be routinely performed on
sputum, results will lag by 1–2 weeks. Nevertheless, the
vastly increased resolution of WGS results means a more
accurate and comprehensive picture of resistance predic-
tion than is currently possible.
In addition, the ability to inform transmission detection,
without the need for extra tests, and the comparability of
cost ensure that the use of WGS in clinical microbiology
is just a matter of how and when, rather than if. Current
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indications are that dual testing (WGS and DST) is only
marginally more expensive than WGS alone, and while
certainty in phenotypic resistance is not yet (if at all) pos-
sible, it would be prudent to maintain DST in the standard
workflow. More research focusing on the realities of clin-
ical management and economic benefits and constraints
in different environments will be immensely valuable.
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